|
1
|
Aune D, Navarro Rosenblatt DA, Chan DS,
Vingeliene S, Abar L, Vieira AR, Greenwood DC, Bandera EV and Norat
T: Anthropometric factors and endometrial cancer risk: A systematic
review and dose-response meta-analysis of prospective studies. Ann
Oncol. 26:1635–1648. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Marnitz S and Köhler C: Current therapy of
patients with endometrial carcinoma. A critical review.
Strahlenther Onkol. 188:12–20. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liotta LA and Kohn EC: The
microenvironment of the tumour-host interface. Nature. 411:375–379.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Trimboli AJ, Cantemir-Stone CZ, Li F,
Wallace JA, Merchant A, Creasap N, Thompson JC, Caserta E, Wang H,
Chong JL, et al: Pten in stromal fibroblasts suppresses mammary
epithelial tumors. Nature. 461:1084–1091. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cirri P and Chiarugi P:
Cancer-associated-fibroblasts and tumour cells: A diabolic liaison
driving cancer progression. Cancer Metastasis Rev. 31:195–208.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tiwari N, Gheldof A, Tatari M and
Christofori G: EMT as the ultimate survival mechanism of cancer
cells. Semin Cancer Biol. 22:194–207. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zeisberg M and Neilson EG: Biomarkers for
epithelial-mesenchymal transitions. J Clin Invest. 119:1429–1437.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Acloque H, Adams MS, Fishwick K,
Bronner-Fraser M and Nieto MA: Epithelial-mesenchymal transitions:
The importance of changing cell state in development and disease. J
Clin Invest. 119:1438–1449. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chaw SY, Majeed AA, Dalley AJ, Chan A,
Stein S and Farah CS: Epithelial to mesenchymal transition (EMT)
biomarkers-E-cadherin, beta-catenin, APC and Vimentin-in oral
squamous cell carcinogenesis and transformation. Oral Oncol.
48:997–1006. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nakajima S, Doi R, Toyoda E, Tsuji S, Wada
M, Koizumi M, Tulachan SS, Ito D, Kami K, Mori T, et al: N-cadherin
expression and epithelial-mesenchymal transition in pancreatic
carcinoma. Clin Cancer Res. 10:4125–4133. 2014. View Article : Google Scholar
|
|
13
|
Islam S, Carey TE, Wolf GT, Wheelock MJ
and Johnson KR: Expression of N-cadherin by human squamous
carcinoma cells induces a scattered fibroblastic phenotype with
disrupted cell-cell adhesion. J Cell Biol. 135:1643–1654. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Giannoni E, Bianchini F, Masieri L, Serni
S, Torre E, Calorini L and Chiarugi P: Reciprocal activation of
prostate cancer cells and cancer associated fibroblasts stimulates
epithelial-mesenchymal transition and cancer stemness. Cancer Res.
70:6945–6956. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schmalhofer O, Brabletz S and Brabletz T:
E-cadherin, beta-catenin, and ZEB1 in malignant progression of
cancer. Cancer Metastasis Rev. 28:151–166. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim SH, Choe C, Shin YS, Jeon MJ, Choi SJ,
Lee J, Bae GY, Cha HJ and Kim J: Human lung cancer-associated
fibroblasts enhance motility of non-small cell lung cancer cells in
co-culture. Anticancer Res. 33:2001–2009. 2013.PubMed/NCBI
|
|
17
|
Du Y, Long Q, Zhang L, Shi Y, Liu X, Li X,
Guan B, Tian Y, Wang X, Li L and He D: Curcumin inhibits
cancer-associated fibroblast-driven prostate cancer invasion
through MAOA/mTOR/HIF-1α signaling. Int J Oncol. 47:2064–2072.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Räsänen K and Vaheri A: Activation of
fibroblasts in cancer stroma. Exp Cell Res. 316:2713–2722. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tlsty TD and Coussens LM: Tumor stroma and
regulation of cancer development. Annu Rev Pathol. 1:119–150. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Matsumoto K and Nakamura T: Hepatocyte
growth factor and the Met system as a mediator of tumor-stromal
interactions. Int J Cancer. 119:477–483. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Birchmeier C, Birchmeier W, Gherardi E and
Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol
Cell Biol. 4:915–925. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tyan SW, Kuo WH, Huang CK, Pan CC, Shew
JY, Chang KJ, Lee EY and Lee WH: Breast cancer cells induce
cancer-associated fibroblasts to secrete hepatocyte growth factor
to enhance breast Tumorigenesis. PLoS One. 6:e153132011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Padua D, Zhang XH, Wang Q, Nadal C, Gerald
WL, Gomis RR and Massagué J: TGFbeta primes breast tumors for lung
metastasis seeding through angiopoietin-like 4. Cell. 133:66–77.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jiang W, Hiscox S, Matsumoto K and
Nakamura T: Hepatocyte growth factor/scatter factor, its molecular,
cellular and clinical implications in cancer. Crit Rev Oncol
Hematol. 29:209–248. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang C, Fu L, Fu J, Hu L, Yang H, Rong
TH, Li Y, Liu H, Fu SB, Zeng YX and Guan XY: Fibroblast growth
factor receptor 2-positive fibroblasts provide a suitable
microenvironment for tumor development and progression in
esophageal carcinoma. Clin Cancer Res. 15:4017–4027. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Achyut BR and Yang L: Transforming growth
factor-β in the gastrointestinal and hepatic tumor
microenvironment. Gastroenterology. 141:1167–1178. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Subramaniam KS, Omar IS, Kwong SC, Mohamed
Z, Woo YL, Mat Adenan NA and Chung I: Cancer-associated fibroblasts
promote endometrial cancer growth via activation of
interleukin-6/STAT-3/c-Myc pathway. Am J Cancer Res. 6:200–213.
2016.PubMed/NCBI
|
|
28
|
Hua T, Liu S, Xin X, Cai L, Shi R, Chi S,
Feng D and Wang H: S100A4 promotes endometrial cancer progress
through epithelial-mesenchymal transition regulation. Oncol Rep.
35:3419–3426. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ostman A and Augsten M: Cancer-associated
fibroblasts and tumor growth-bystanders turning into key players.
Curr Opin Genet Dev. 19:67–73. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Teng F, Tian WY, Wang YM, Zhang YF, Guo F,
Zhao J, Gao C and Xue FX: Cancer-associated fibroblasts promote the
progression of endometrial cancer via the SDF-1/CXCR4 axis. J
Hematol Oncol. 9:8–22. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Subramaniam KS, Tham ST, Mohamed Z, Woo
YL, Mat Adenan NA and Chung I: Cancer-associated fibroblasts
promote proliferation of endometrial cancer cells. PLoS One.
8:e689232013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hwang RF, Moore T, Arumugam T,
Ramachandran V, Amos KD, Rivera A, Ji B, Evans DB and Logsdon CD:
Cancer-associated stromal fibroblasts promote pancreatic tumor
progression. Cancer Res. 68:918–926. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Olumi AF, Grossfeld GD, Hayward SW,
Carroll PR, Tlsty TD and Cunha GR: Carcinoma-associated fibroblasts
direct tumor progression of initiated human prostatic epithelium.
Cancer Res. 59:5002–5011. 1999.PubMed/NCBI
|
